Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Echistatin is a potent inhibitor of bone resorption in culture.

Sato M, Sardana MK, Grasser WA, Garsky VM, Murray JM, Gould RJ.

J Cell Biol. 1990 Oct;111(4):1713-23.

2.

Structure-activity studies of the s-echistatin inhibition of bone resorption.

Sato M, Garsky V, Majeska RJ, Einhorn TA, Murray J, Tashjian AH Jr, Gould RJ.

J Bone Miner Res. 1994 Sep;9(9):1441-9.

PMID:
7817829
3.

Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis.

Horton MA, Dorey EL, Nesbitt SA, Samanen J, Ali FE, Stadel JM, Nichols A, Greig R, Helfrich MH.

J Bone Miner Res. 1993 Feb;8(2):239-47.

PMID:
7680185
4.

Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation.

van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S, Löwik C.

J Bone Miner Res. 1994 Jul;9(7):1021-8.

PMID:
7942148
5.
6.

Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.

Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M.

Endocrinology. 1993 Mar;132(3):1411-3.

PMID:
8440195
7.

Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT.

J Cell Sci. 1999 Nov;112 ( Pt 22):3985-93.

8.

Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts.

Shankar G, Davison I, Helfrich MH, Mason WT, Horton MA.

J Cell Sci. 1993 May;105 ( Pt 1):61-8.

9.
10.
11.

Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.

Carron CP, Meyer DM, Engleman VW, Rico JG, Ruminski PG, Ornberg RL, Westlin WF, Nickols GA.

J Endocrinol. 2000 Jun;165(3):587-98.

12.

Effects of kistrin on bone resorption in vitro and serum calcium in vivo.

King KL, D'Anza JJ, Bodary S, Pitti R, Siegel M, Lazarus RA, Dennis MS, Hammonds RG Jr, Kukreja SC.

J Bone Miner Res. 1994 Mar;9(3):381-7.

PMID:
8191932
13.

Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption.

Helfrich MH, Nesbitt SA, Lakkakorpi PT, Barnes MJ, Bodary SC, Shankar G, Mason WT, Mendrick DL, Väänänen HK, Horton MA.

Bone. 1996 Oct;19(4):317-28.

PMID:
8894137
14.
15.
16.

Chemical synthesis of echistatin, a potent inhibitor of platelet aggregation from Echis carinatus: synthesis and biological activity of selected analogs.

Garsky VM, Lumma PK, Freidinger RM, Pitzenberger SM, Randall WC, Veber DF, Gould RJ, Friedman PA.

Proc Natl Acad Sci U S A. 1989 Jun;86(11):4022-6.

17.

The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats.

Yamamoto M, Fisher JE, Gentile M, Seedor JG, Leu CT, Rodan SB, Rodan GA.

Endocrinology. 1998 Mar;139(3):1411-9.

PMID:
9492078
18.

Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption.

Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL, Cheresh DA.

J Biol Chem. 1993 May 5;268(13):9901-7.

20.

Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells.

Nakamura I, Tanaka H, Rodan GA, Duong LT.

Endocrinology. 1998 Dec;139(12):5182-93.

PMID:
9832459

Supplemental Content

Support Center